---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-069941"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-08-16T23:59:59+00:00"
generated_at: "2026-05-31T08:54:06.992136+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics announces 1-for-15 reverse stock split effective Aug 20, 2024

## Summary
- Reverse stock split ratio set at 1-for-15; effective at 12:01 a.m. ET on August 20, 2024.
- Outstanding shares reduced from ~16M to ~1.1M; no fractional shares; cash paid in lieu.
- New CUSIP number 127636 207; stock continues trading under CVKD on Nasdaq.
- Split intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.
- Proportional adjustments made to equity awards, warrants, and exercise prices.

## SEC filing metadata
- accession: 0001213900-24-069941
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/0001213900-24-069941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/ea021156901-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-069941
- JSON: https://secwatch.observer/filing/0001213900-24-069941.json
- Plain text: https://secwatch.observer/filing/0001213900-24-069941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.